Comparative Study of Early Efficacy of Once-Daily Dosing between Silodosin 4mg and Tamsulosin 0.2mg for Voiding Symptoms Associated with Benign Prostatic Hyperplasia - Comparative Study of Early Efficacy of Once-Daily Dosing between Silodosin 4mg and Tamsulosin 0.2mg for Voiding Symptoms Associated with Benign Prostatic Hyperplasia

Matsushita Urology Clinic0 个研究点目标入组 60 人开始时间: 2013年8月26日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•(1)Subject is contraindicated to silodosin or tamsulosin according to the respective package insert. (2)Subject has received prostatic resection. (3)Subject has received radiotherapy to the pelvic region. (4)Subject has received hyperthermia or thermotherapy for prostatic hypertrophy. (5)Subject has or is suspected to have prostate cancer. (6)Subject has neurogenic overactive bladder, bladder neck contracture, urethral stricture, bladder stones, large bladder diverticulum, active urinary tract infection requiring treatment, or other complications that may affect urination. (7)Subject performs self-catheterization. (8)Subject has taken any of the following drugs within 12 months before the start of treatment period (Day 0): * silodosin or tamsulosin, * 5alpha-reductase inhibitors, or * antiandrogen drugs. (9)Subject has clinically important cardiovascular disturbances. (10)Subject has clinically important hepatorenal diseases. (11)Subject has a history of severe drug hypersensitivity. (12)Subject is scheduled to have cataract surgery in the study period. (13)Subject has or is suspected to have a complication of dementia. (14)Subject is considered inappropriate for participating in the study by the subinvestigator.

发起方

Matsushita Urology Clinic